John Theurer Cancer Center | |
---|---|
Geography | |
Location | 92 2nd Street, Hackensack, New Jersey, United States |
Organization | |
Funding | Non-profit hospital |
Type | Cancer treatment |
Affiliated university | Hackensack University Medical Center
Georgetown Lombardi Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center |
Network | Hackensack Meridian Health |
Links | |
Lists | Hospitals in the United States |
John Theurer Cancer Center (JTCC) at the Hackensack University Medical Center (HUMC), and part of the Hackensack Meridian Health (HMH), specializes in oncology services and treatments.[1] It is known for being the first site approved to use cell-based gene therapy to treat patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment; it initiated the first CAR T-cell therapy clinical trials and is a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center. Other areas of concentration include bone marrow transplants, stem cell transplantation, lymphoma, leukemia, multiple myeloma, neuro-oncology, cutaneous malignancy, gastrointestinal, geriatric, head and neck, thoracic, urologic, breast, and gynecologic.[2] As of 2023, Andre Goy is chair and Chief Physician Officer.[3][4][5]
In 2019, JTCC received approval from the National Cancer Institute (NCI) as a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center.[6] The partnership focuses on advancing research and treatment in breast cancer, cancer prevention and control, experimental therapeutics and molecular oncology.[7][8][9] The Georgetown Lombardi Comprehensive Center is designated by the National Cancer Institute as a leader in cancer treatment.[10]
JTCC is part of Hackensack University Medical Center. HUMC and part of the Hackensack Meridian Health network, which includes Joseph M. Sanzari Children's Hospital, the Cancer Center, a branch of The Betty Torricelli Institute for Breast Care, Ocean Medical Center, Pascack Valley Medical Center, and the Riverview Medical Center.[11][12][13]
In 2022, JTCC expanded its program to Hackensack Meridian Jersey Shore University Medical Center's HOPE Tower, providing access to specialized cancer services and access to clinical trials.[14]
JTCC has a partnership with Memorial Sloan Kettering Cancer Center (MSK) to provide cancer care and develop joint standards of care through the oversight of a governing board composed of members from both MSK and HMH.[15]
In 2021, JTCC entered into a clinical affiliation with Regional Cancer Care Associates (RCCA) to open a practice called Toms River Regional Cancer Center in Toms River, NJ. The center provides comprehensive medical and surgical oncology/hematology consultative services by community-based, regional, and national specialists for various types and stages of cancer and serious blood disorders.[13]
In 2022, JTCC entered into a clinical affiliation with St. Joseph's Health to provide expanded cancer care services to the residents of Wayne, Paterson, and Totowa.
In 2011, JTCC at HUMC opened a $130-million, 155,000-sq. ft. facility.[1] The JTCC pavilion was built with a green roof, providing patients and visitors with a relaxing environment[16] and doubling as exterior insulation—greatly reducing heat gain and loss.[17] This reduces energy use for heating and cooling as well as harmful emissions.[18]